Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of this study is to evaluate the PMPA gel, which kills microbes, in HIV-infected and HIV-uninfected women. The majority of new HIV infections occur through heterosexual contact. A product that stops or slows the replication of HIV during sexual contact is needed. At present, there are no products that are completely effective. PMPA gel, also known as tenofovir, is an anti-microbe agent that may fight against sexual transmission of HIV and other sexually transmitted diseases (STDs). It is applied to the vagina and gives women the ability to control their disease-prevention activity.

Key facts

Study ID

NCT00028132

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

120

Expected to finish

2005-12-01

Last updated by the study team

2021-11-01

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All female participants may be eligible for this study if they:
• Are between 18 and 45 years of age.
• Have a menstrual cycle with at least 21 days between periods or have not menstruated for at least 6 months.
• Agree from the time of Screening Visit until the Day 14 Follow-up Visit to: a) not use IV drugs (except for therapeutic use) and b) not participate in other microbicide or contraceptive studies.
• Agree not to take part in the following activities for at least 48 hours before the study enrollment visit (Day 0) until the Day 14 Follow-up Visit: anal intercourse; douching; oral contact with the vagina; penetration of the vagina by fingers, sex toys, or any other objects; use of any vaginal product, including lubricants, drying agents, feminine hygiene products, diaphragms, and cervical caps.
• Agree to insert the PMPA gel in the exact way it is specified.
• Abstinent Women (Groups A1-A4, C, and V) may be eligible for this study if they:
• Agree to abstain from vaginal intercourse from 48 hours before study until Day 14.
• HIV-infected abstinent women (C) must be HIV infected; have a CD4 count of at least 200/mm3 at time of screening and within 6 months prior to screening, and a viral load of 10,000 copies/ml or less if on anti-HIV therapy or have a viral load of less than 55,000 if not on anti-HIV therapy; provide study staff access to HIV medical records and be under medical care for HIV management; and be on stable anti-HIV therapy (if any) for 1 month before screening and expect to stay on that therapy throughout the study.
• Sexually Active Women (Groups B and D) may be eligible for this study if they:
• Agree to abstain from vaginal intercourse for 48 hours before study start.
• Agree to tell their mutually monogamous male sexual partner about their participation in the trial and of requirements from Day 0 until Day 14 to have vaginal intercourse at least twice weekly and to use a study-provided male latex condom for every sexual episode.
• HIV-uninfected sexually active women (B) must currently have a single male HIV-uninfected sexual partner who is at low risk for HIV infection and who can be included in the study.
• HIV-infected sexually active women (D) must have a CD4 count of at least 200/mm3 at time of screening and within 6 months prior to screening, and a viral load of 10,000 copies/ml or less if on anti-HIV therapy or have a viral load of less than 55,000 if not on anti-HIV therapy; provide study staff access to HIV medical records and be under medical care for HIV management; be on stable anti-HIV therapy (if any) for 1 month before screening and expect to stay on that therapy throughout the study; and currently have a single male HIV-infected sexual partner who can be included in the study.
• Male sexual partners of sexually active participants (Groups B and D) must be:
• At least 18 years old and in a relationship with the study participant for at least 3 months and be willing to maintain this relationship for the entire study.
• At low risk for HIV infection and be HIV-uninfected if female partner is HIV-uninfected (B) or be HIV-infected if female partner is HIV-infected (D).
• Able and willing to have vaginal intercourse with only the study participant at least 2 times per week, and to use study-provided lubricated male condoms each time during study.
• Willing to not have vaginal intercourse for 48 hours before Day 0.
• Willing to abstain from the following from 48 hours before Day 0 until the end of study product use: anal intercourse, oral contact with the vagina, and penetration of the vagina by fingers, sex toys, or any other objects.
• Willing to take part in an interview after the study and undergo clinical evaluations.
• (This study has been changed to expand the CD4 cell count criterion for Groups C and D.)

You may not qualify if…

• Female participants may not be eligible for this study if they:
• Have gone through menopause.
• Have had a hysterectomy.
• Are breast-feeding.
• Are using or have used within the past year IV drugs (except for therapeutic use).
• Are pregnant.
• Have serious liver, kidney, or blood problems.
• Have had antibiotic therapy in the 14 days before study start.
• Have taken part in other microbicide or contraceptive studies within 1 month of study start.
• Have been previously enrolled in this study.
• Have any genital abnormalities.
• Are sensitive or allergic to any substances used in the study.
• Are unwilling to use 1 of the following methods of contraception during the study unless surgically sterilized: non N-9 condoms, hormonal contraceptives, abstinence.
• Have used any spermicide or condoms that have spermicide on them within 1 week before study start.
• Have used a hormonal contraceptive method for less than 3 months before study start.
• Have had any of the following in the 3 months before study start: vaginal bleeding during or following vaginal intercourse; breakthrough menstrual bleeding; an IUD; an abnormal Pap smear; a pregnancy; an abortion; or gynecologic surgery.
• Have had, in the 6 months before study start, an STD or treatment for any STD, signs of an STD, or signs of genital tract infection.
• Have any other condition that, in the opinion of the doctor, would be unsafe for the participant or would interfere with the study.
• Male sexual partners may not be eligible for this study if they have:
• Been treated for STDs or presumed STDs within 6 months before study start.
• Symptoms of STDs that cannot be evaluated within 2 weeks of study start.
• Sensitivity or allergy to any substance used in the study.
• Any other condition that, in the opinion of the doctor, would be unsafe for the participant or would interfere with the study.

Where it is running

• Harlem Prevention Ctr. CRS (El-Sadr CTU) — New York, New York, United States
• Bronx- Lebanon Hospital Center Clinical Research Site (BLHC CRS) — The Bronx, New York, United States
• 3535 Market Street CRS — Philadelphia, Pennsylvania, United States
• The Miriam Hosp., Div. of Infectious Disease — Providence, Rhode Island, United States
• Women & Infants' Hosp. — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.